Figure 2 HGF/c-MET signalling pathway

Slides:



Advertisements
Similar presentations
“Signal transduction biochemistry: a field afflicted with many facts and blessed with only a few unifying principles.” R. A. Weinberg.
Advertisements

Growth Factors and Enzyme- Linked Receptor Signal Systems Lecture 29BSCI 420/421Nov 8, 2002 “If we have concluded that we are being asked to take senseless.
STAT3 Michael Patel.
The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Copyright © 2015 by the American Osteopathic Association.
Figure 2 Inflammatory pathways affecting hepatic insulin resistance
Sustaining Proliferative Signaling and Evading Growth Suppressors
Sustaining Proliferative Signaling and Evading Growth Suppressors
Figure 4 The mechanistic link between the epithelial-to-mesenchymal
Figure 3 The contribution of the tumour microenvironment
Figure 4 Simplified T cell and antigen presenting
You have identified a novel cytoplasmic protein
Miriam Marqués, Francisco X. Real  European Urology 
The Cbl Family and Other Ubiquitin Ligases
Figure 1 Signalling pathways involved in muscle wasting in heart failure Figure 1 | Signalling pathways involved in muscle wasting in heart failure. Pathways.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 The cell cycle and the role of CDK4/6 inhibition
Figure 1 The multidomain structure of c-MET and its ligand, HGF
Figure 4 Involvement of SEMA4D in the pathogenesis
cMET Exon 14 Skipping: From the Structure to the Clinic
Figure 4 Possible combination therapies CDK4/6 inhibitors
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 CAR-T-cell design
Figure 1 A schematic representation of the HER2 signalling pathway
Signal Transduction Through the Epidermal Growth Factor Receptor
Signaling molecules as therapeutic targets in allergic diseases
Figure 2 Oestrogen receptor signalling pathways
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Urol. doi: /nrurol
Figure 1 Therapeutic targeting of the B-cell receptor (BCR)
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 mTOR complex biology
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 WNT signalling pathways
Figure 5 The mechanism underlying epithelial-to-mesenchymal
David M. Lonard, Bert W. O'Malley  Molecular Cell 
Great Expectations for PIP: Phosphoinositides as Regulators of Signaling During Development and Disease  Lara C. Skwarek, Gabrielle L. Boulianne  Developmental.
David M. Lonard, Bert W. O'Malley  Molecular Cell 
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 The insulin signalling pathway
Vascular Endothelial Growth Factor (VEGF) Pathway
Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway
Summary of lipid raft-associated signaling pathways involved in Afa/Dr DAEC pathogenesis. Summary of lipid raft-associated signaling pathways involved.
Nat. Rev. Rheumatol. doi: /nrrheum
Met as a therapeutic target in HCC: Facts and hopes
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Control of Smad7 stability by competition between Acetylation and Ubiquitination Gronroos et al., 2002, Mol Cell.
Figure 1 Mechanisms of action of immunotherapy modalities
Signal Transduction Through the Epidermal Growth Factor Receptor
SRC and STAT Pathways Journal of Thoracic Oncology
Signalling links in the liver: Knitting SOCS with fat and inflammation
Nat. Rev. Clin. Oncol. doi: /nrclinonc
SOCS Proteins, Regulators of Intracellular Signaling
Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD 
Platelet-derived growth factor (PDGF) signalling pathway.
GPC5 Gene and Its Related Pathways in Lung Cancer
Inhibition of VEGF-R2-mediated signalling cascade by endogenous antagonists. Inhibition of VEGF-R2-mediated signalling cascade by endogenous antagonists.
Components and outcomes of selected TNF-superfamily signalling pathways. Components and outcomes of selected TNF-superfamily signalling pathways. (Left)
Figure 2 Signalling downstream of the IL-6 receptor
Volume 7, Issue 1, Pages 1-11 (July 1997)
Figure 5 TLR-dependent signaling pathways inhibited by glatiramer acetate Myeloid differentiation primary response gene 88 (MyD88) and Toll-IL-1 receptor.
Nat. Rev. Urol. doi: /nrurol
Brief Review – Growth Factors and Receptors
Cell Signaling by Receptor Tyrosine Kinases
Characterization of the MM.1 human multiple myeloma (MM) cell lines
Overview of molecular JAK signaling.
The Cbl Family and Other Ubiquitin Ligases
Presentation transcript:

Figure 2 HGF/c-MET signalling pathway components, interaction network, and mechanisms of negative regulation Figure 2 | HGF/c-MET signalling pathway components, interaction network, and mechanisms of negative regulation. HGF induces dimerization and transautophosphorylation of c-MET, resulting in the recruitment of several Src homology 2 (SH2)-domain-containing signalling proteins, activation of downstream effector signalling, including the growth factor receptor-bound protein 2 (GRB2)–son of sevenless homologue 1 (SOS)–RAS–MAPK cascade, the PI3K/AKT axis, signal transducer and activator of transcription 3 (STAT3), SRC/FAK and rho-like GTPases such as ras-related C3 botulinum toxin substrate 1 (RAC1). Lateral cooperation with an interaction network, including the laminin receptor α6β4 integrin, the hyaluronan receptor CD44v6, and members of the semaphorin plexin B family, amplifies signal transduction, thereby sustaining c-MET signalling. The pathway can be negatively regulated by proteolytic cleavage by the a disintegrin and metalloproteinase (ADAM) family and γ-secretase, resulting in inhibition of c-MET signalling by soluble c-MET. c-MET can be internalized and degraded in lysosomes, or recycled to the cell surface. CBL, E3 ubiquitin-protein ligase CBL; EMT, epithelial-to-mesenchymal transition; NF-κB, nuclear factor-κB; PLC-γ, phospholipase Cγ; SHP2, tyrosine-protein phosphatase non-receptor type 11. Bradley, C. A. et al. (2017) Targeting c‑MET in gastrointestinal tumours: rationale, opportunities and challenges Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.40